Matches in SemOpenAlex for { <https://semopenalex.org/work/W1924029751> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W1924029751 endingPage "e119" @default.
- W1924029751 startingPage "e119" @default.
- W1924029751 abstract "Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are effective as two first-line anti-viral therapies for chronic hepatitis B (CHB); however, data are limited on directly comparing these two antivirals. This study aimed to compare the effectiveness and safety of TDF and ETV initial treatment of CHB patients. From October 2008 to December 2013, 257 consecutive treatment-naive CHB patients receiving TDF (n = 79) or ETV (n = 178) at Taipei Veterans General Hospital were enrolled. The baseline characteristics were comparable between the two groups. Kaplan-Meier curve estimated probability of complete HBV DNA suppression was 56.5% vs 75.9% at 6 months (P = .003), 81.7% vs 89.9% at 12 months (P = .098) and 93.3% vs 96.2% at 24 months (P = .565) in ETV and TDF group, respectively. Multivariate Cox regression indicated that treatment with TDF compared to ETV was a significant predictor of HBV DNA suppression (HR = 1.33; 95% CI 1.01-1.76; P = .045). In addition, HBAg positive (HR = 0.70; 95% CI 0.52-0.96; P = .025) and higher baseline HBV DNA level (HR = 0.84; 95% CI 0.76-0.92; P < .001) were significant negative predictors for viral suppression. The ALT normalization rate between these two treatment groups were not statistically significant (P = .114). Estimated glomerular filtration rate (eGFR) calculated by MDRD formula significantly decreased in both group at 24 months (-6.4027 in ETV vs -16.0556 in TDF, P = .006). Multivariate analysis indicated that TDF and baseline eGFR were independent factors associated with change of eGFR at 24 months. However, a small amount of patients progressed into moderate renal dysfunction during 24 months (0.7% vs 5.6%, P = .058). TDF was significantly more effective in achieving complete viral suppression, whereas it was also more significant in reduction of eGFR than ETV group." @default.
- W1924029751 created "2016-06-24" @default.
- W1924029751 creator A5013129858 @default.
- W1924029751 creator A5035542029 @default.
- W1924029751 creator A5064901548 @default.
- W1924029751 date "2015-07-01" @default.
- W1924029751 modified "2023-09-25" @default.
- W1924029751 title "Comparison Between Tenofovir and Entecavir Treatment in Real-World Clinical Practice" @default.
- W1924029751 doi "https://doi.org/10.1016/j.cgh.2015.04.154" @default.
- W1924029751 hasPublicationYear "2015" @default.
- W1924029751 type Work @default.
- W1924029751 sameAs 1924029751 @default.
- W1924029751 citedByCount "0" @default.
- W1924029751 crossrefType "journal-article" @default.
- W1924029751 hasAuthorship W1924029751A5013129858 @default.
- W1924029751 hasAuthorship W1924029751A5035542029 @default.
- W1924029751 hasAuthorship W1924029751A5064901548 @default.
- W1924029751 hasConcept C126322002 @default.
- W1924029751 hasConcept C159641895 @default.
- W1924029751 hasConcept C203014093 @default.
- W1924029751 hasConcept C2522874641 @default.
- W1924029751 hasConcept C2775940106 @default.
- W1924029751 hasConcept C2776175608 @default.
- W1924029751 hasConcept C2777382497 @default.
- W1924029751 hasConcept C2777410769 @default.
- W1924029751 hasConcept C2777869810 @default.
- W1924029751 hasConcept C2779344132 @default.
- W1924029751 hasConcept C2780593183 @default.
- W1924029751 hasConcept C3013748606 @default.
- W1924029751 hasConcept C50382708 @default.
- W1924029751 hasConcept C71924100 @default.
- W1924029751 hasConcept C90924648 @default.
- W1924029751 hasConceptScore W1924029751C126322002 @default.
- W1924029751 hasConceptScore W1924029751C159641895 @default.
- W1924029751 hasConceptScore W1924029751C203014093 @default.
- W1924029751 hasConceptScore W1924029751C2522874641 @default.
- W1924029751 hasConceptScore W1924029751C2775940106 @default.
- W1924029751 hasConceptScore W1924029751C2776175608 @default.
- W1924029751 hasConceptScore W1924029751C2777382497 @default.
- W1924029751 hasConceptScore W1924029751C2777410769 @default.
- W1924029751 hasConceptScore W1924029751C2777869810 @default.
- W1924029751 hasConceptScore W1924029751C2779344132 @default.
- W1924029751 hasConceptScore W1924029751C2780593183 @default.
- W1924029751 hasConceptScore W1924029751C3013748606 @default.
- W1924029751 hasConceptScore W1924029751C50382708 @default.
- W1924029751 hasConceptScore W1924029751C71924100 @default.
- W1924029751 hasConceptScore W1924029751C90924648 @default.
- W1924029751 hasIssue "7" @default.
- W1924029751 hasLocation W19240297511 @default.
- W1924029751 hasOpenAccess W1924029751 @default.
- W1924029751 hasPrimaryLocation W19240297511 @default.
- W1924029751 hasRelatedWork W1912024884 @default.
- W1924029751 hasRelatedWork W2087157518 @default.
- W1924029751 hasRelatedWork W2321746760 @default.
- W1924029751 hasRelatedWork W2572806582 @default.
- W1924029751 hasRelatedWork W2771386081 @default.
- W1924029751 hasRelatedWork W2896700797 @default.
- W1924029751 hasRelatedWork W2945892858 @default.
- W1924029751 hasRelatedWork W3044601235 @default.
- W1924029751 hasRelatedWork W3119913921 @default.
- W1924029751 hasRelatedWork W4200348393 @default.
- W1924029751 hasVolume "13" @default.
- W1924029751 isParatext "false" @default.
- W1924029751 isRetracted "false" @default.
- W1924029751 magId "1924029751" @default.
- W1924029751 workType "article" @default.